Answers are grounded in this paper and cite their sources.
The FDA's decision not to approve generic versions of original-formula OxyContin may keep drug costs high for patients with pain, but the benefits of the newer, abuse-resistant formulation outweigh this harm.
No takes yet. Share an insight, caveat, or question.
Gary M. Reisfield (2014) studied this question.
Synapse has enriched 8 related papers. Consider them for comparative context: